<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04576546</url>
  </required_header>
  <id_info>
    <org_study_id>MI_DCI_FSH</org_study_id>
    <nct_id>NCT04576546</nct_id>
  </id_info>
  <brief_title>Inositols and FSH in IVF</brief_title>
  <official_title>Use of Inositols Within IVF Protocols to Reduce Gonadotropin Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lo.Li.Pharma s.r.l</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lo.Li.Pharma s.r.l</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ovarian hyperstimulation syndrome (OHSS), although quite uncommon, represents the most&#xD;
      serious complication of ovulation induction during in-vitro fertilization (IVF) protocols.&#xD;
      The syndrome is triggered by exaggerated ovarian response to gonadotropins, which eventually&#xD;
      leads to pathological manifestations that range from mild symptoms, such as abdominal&#xD;
      discomfort, to life-threatening complications in the most severe cases. Prevention is&#xD;
      paramount during fertilization programs and requires assessment of risk factors and close&#xD;
      monitoring of risk markers. Clinicians quite generally consider unusually elevated estrogen&#xD;
      levels as both indicator for OHSS and one possible etiological factor. In this scenario,&#xD;
      myo-inositol (MYO) treatment proved to reduce the amount of FSH units and the duration of the&#xD;
      stimulation protocol, decreasing the risk of OHSS onset. On the other hand, inconclusive&#xD;
      evidence is available about the effect of D-chiro-inositol (DCI) supplementation within&#xD;
      assisted reproductive treatments. The aim of the proposed pilot study is to assess the effect&#xD;
      of DCI supplementation on the doses of FSH used in IVF-ET protocols, also with respect to MYO&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FSH units/retrieved oocyte</measure>
    <time_frame>1 day (single time-point at ovulation)</time_frame>
    <description>number of IU of recombinant FSH administered, normalized on the number of oocytes retrieved during the pick-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total FSH (IU)</measure>
    <time_frame>1 day (single time-point at ovulation)</time_frame>
    <description>total number of FSH IU used in the stimulation protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the stimulation</measure>
    <time_frame>1 day (single time-point at ovulation)</time_frame>
    <description>Number of days of the stimulation protocol till pick-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of viable oocytes</measure>
    <time_frame>1 day (single time-point at oocyte pick-up)</time_frame>
    <description>number of retrieved oocytes eligible for fortilization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oocyte quality</measure>
    <time_frame>1 day (single time-point at oocyte pick-up)</time_frame>
    <description>classification of oocyte quality before fertilization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>embryo quality</measure>
    <time_frame>1 day (single time-point at embryo transfer)</time_frame>
    <description>evaluation of the quality of embryos after fertilization, before transfer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Amount of FSH Units During Ovarian Stimulation Protocols</condition>
  <arm_group>
    <arm_group_label>comparator group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>myo-inositol treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D-chiro-inositol treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>D-chiro-inositol</intervention_name>
    <description>Supplementation of D-chiro-inositol (1000 mg/die), starting at least 4 weeks before rFSH administration</description>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Myo-inositol</intervention_name>
    <description>Supplementation of myo-inositol (4 g/die), starting at least 4 weeks before rFSH administration</description>
    <arm_group_label>comparator group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women undergoing IVF-ET procedure&#xD;
&#xD;
          -  HOMA-IR index &lt; 2.0&#xD;
&#xD;
          -  AMH in the range 1.0 - 2.0 ng/ml&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of cancelled IVF cycles&#xD;
&#xD;
          -  BMI &lt; 20 kg/m2 or â‰¥ 30 kg/m2&#xD;
&#xD;
          -  Diagnosis of PCOS&#xD;
&#xD;
          -  Thyroid diseases&#xD;
&#xD;
          -  Presence of co-morbidities&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cesare Aragona, MD</last_name>
    <phone>+39 348 4043527</phone>
    <email>aragonacesare@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinica Alma Res</name>
      <address>
        <city>Roma</city>
        <zip>00198</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesare Aragona, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>October 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2020</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

